Published Date: 13 Mar 2023
New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Study finds primary-care doctors often overlook prostate cancer risk in Black men
2.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
3.
When it comes to obesity-related cancers, where you shop for food matters
4.
Drop in credit score after cancer diagnosis linked to increased mortality
5.
Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.
1.
Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders
2.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
3.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
4.
Understanding the HAS-BLED Score: What It Is and Why It Matters
5.
Everything You Need to Know About HTLV: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Q&A Session to Close the Gap
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation